On August 25, 2025, Terumo agreed to acquire OrganOx for $1.5 billion. The transaction closed that October, giving the University of Oxford spinout the largest exit in its history and making OrganOx the first Oxford spinout to surpass £1 billion.
Spun out of Oxford in 2008, OrganOx developed a liver perfusion platform that has been used in more than 5,000 liver transplants over 17 years. The UK company ultimately found its buyer in Terumo, headquartered in Tokyo.
That geographic divide is not unusual. An analysis of European medtech acquisitions logged by Compass AI since January 2025 shows that some of the continent’s most valuable technologies are increasingly finding buyers outside Europe.
13 European medtech acquisitions with disclosed values have totaled $4.24 billion since January 2025, while another six transactions closed without disclosed prices.
Ten Largest Disclosed-Value European Medtech Acquisitions (Since January 2025) |
||||
|
Target |
Country |
Value |
Acquirer |
Acquirer HQ |
|
OrganOx |
UK |
$1.50B |
Terumo |
Japan |
|
Israel |
$585M |
Medtronic |
US / Ireland |
|
|
SoniVie |
Israel |
$540M |
Boston Scientific |
US |
|
Vectorious |
Israel |
$497M |
Edwards Lifesciences |
US |
|
BioProtect |
Israel |
$270M |
Olympus |
Japan |
|
Gleamer |
France |
$269M |
RadNet |
US |
|
Endospan |
Israel |
$175M |
Artivion |
US |
|
LEX Diagnostics |
UK |
~$175M |
QuidelOrtho |
US |
|
SpinChip |
Norway |
~$150M |
bioMérieux |
France |
|
Robocath |
France |
$45M |
Stereotaxis |
US |
Of that $4.24 billion, 95.6% went to companies headquartered outside Europe.
There are a few exceptions. France’s bioMérieux acquired Norwegian diagnostics company SpinChip for approximately $150 million, making it the only European strategic to spend nine figures on a European medtech innovator in 20 months.
The remaining disclosed deals were small and domestic. Affluent Medical acquired Caranx Medical and Artedrone for a combined €28 million before becoming Carvolix. Sweden’s SyntheticMR acquired Finland’s Combinostics for €4.3 million.
Undisclosed transactions reinforce the broader pattern. GE HealthCare acquired Belgium’s icometrix, DePuy Synthes acquired the Gemtrack product line from France’s MinMaxMedical, and Össur acquired Finland’s Dassiet.
Israel stands out within the data. Five of the 13 disclosed transactions involved Israeli targets: CathWorks, SoniVie, Vectorious, BioProtect, and Endospan. Together, those companies accounted for $2.07 billion, or 49% of disclosed exit value.
Financing data shows another form of concentration. Median disclosed round size across European medtech venture deals has climbed sharply over the past five years:
Median Disclosed European Medtech Venture Round Size by Year |
|
|
Year |
Median Round |
|
2020 |
$5.3M |
|
2021 |
$7.8M |
|
2022 |
$7.0M |
|
2023 |
$6.5M |
|
2024 |
$11.0M |
|
2025 |
$17.9M |
The median increased from $5.3 million in 2020 to $17.9 million in 2025. Total capital deployed in 2025 was roughly comparable to 2021, but it was distributed across far fewer companies. Reporting delays for smaller rounds account for some of that difference, but not all of it.
Recent financings illustrate what is happening at the top. Oura raised $908 million, Neko Health $700 million, Aidoc $150 million, Distalmotion $150 million, CeQur $100 million, ViCentra $85 million, and Neurent Medical $74 million.
Capital has not disappeared from the European medtech market. It has become more concentrated.
Across roughly 500 recent European medtech rounds since January 2022, Sofinnova Partners is the most active private investor. The European Innovation Council and EIC Fund, however, collectively participated in more rounds than any investor.
Most Active Investors in European Medtech Since January 2022 |
|
|
Investor |
Rounds |
|
European Innovation Council (incl. EIC Fund) |
20 |
|
Sofinnova Partners |
18 |
|
Bpifrance |
13 |
|
Invest-NL |
9 |
|
Panakès Partners |
9 |
|
Enterprise Ireland |
7 |
|
Wellington Partners |
7 |
|
Atlantic Bridge |
6 |
|
BOM |
6 |
|
SFC Capital |
6 |
|
Supernova Invest |
6 |
Public or state-backed investors participated in 24% of European medtech venture rounds since 2022. Their involvement increased with stage, from 21% of Seed rounds to 27% of Series A rounds and 33% of Series B rounds.
The European Investment Bank is another important source of capital. Recent commitments include €20 million for Precisis, up to €37.5 million for Xeltis, €20 million for SamanTree Medical, and €30 million for TISSIUM.
The 228 innovators heading to LSI Europe ’26 cluster across clinical areas in a way that reflects where recent exits have occurred. Of those companies, 146 are European or Israeli.
|
Clinical Area |
European Companies |
|
Cardiovascular |
55 |
|
Imaging & diagnostics |
50 |
|
AI / software |
50 |
|
Neuro |
42 |
|
Oncology |
34 |
|
Urology & renal |
30 |
|
Orthopedic |
16 |
|
Respiratory |
14 |
|
Surgical robotics |
13 |
Note: Companies tagged in multiple clinical areas may appear more than once.
Cardiovascular is the largest clinical area represented among the LSI Europe ‘26 innovators, followed by imaging and diagnostics and AI/software. That concentration mirrors recent exits. CathWorks, SoniVie, Vectorious, and Endospan all operate in cardiovascular or vascular markets, while imaging and diagnostics transactions include Gleamer’s acquisition by RadNet, icometrix’s acquisition by GE HealthCare, and LEX Diagnostics’ acquisition by QuidelOrtho.
The bigger question is who ultimately owns these technologies. Medtronic, Boston Scientific, Edwards Lifesciences, Olympus, Terumo, RadNet, QuidelOrtho, Artivion, GE HealthCare, and J&J have all bought European medtech innovation in the last 20 months. Large European strategics have been considerably less visible in the same auctions.
Meanwhile, the financing data shows investors concentrating larger amounts of capital into fewer companies, with public and state-backed funding playing a substantial role as companies advance.
Europe is still building valuable medtech companies. The numbers increasingly suggest that the rest of the world is willing to pay for them.
Join the LSI Mailing List
Upcoming Events
17011 Beach Blvd, Suite 500
Huntington Beach, CA 92647
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data